

BLACK ROSE INDUSTRIES LTD.

Q3 FY2021-22 EARNINGS WEBINAR February 9, 2022

Mr. Anup Jatia – Executive Director

Mr. Ambarish Daga – Joint CFO and Investor Relations Officer



Q3 FY2021-22 EARNINGS WEBINAR

Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **BLACK ROSE INDUSTRIES LTD.** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost overruns on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Q3 FY2021-22 EARNINGS WEBINAR



Chemical distribution

Import and distribution of specialty and performance chemicals

Acrylamide liquid – 32,000 MTPA

(20,000 MTPA for merchant sales and 12,000 MTPA for captive requirement) Polyacrylamide solid -10,000 MTPA (in R&D)

Chemical manufacturing

N-methylol acrylamide (NMA) - 2,000 MTPA

Polyacrylamide liquid - 40,000 MTPA Acrylamide solid - 3,600 MTPA (awaiting clearance)

Legacy/other businesses: The Company is also engaged in the manufacture of fabrics and made-ups for industrial applications at Kolhapur (Maharashtra), and renewable energy (a windmill each in Gujarat and Rajasthan). **These businesses contribute less than 1% to the company's revenues.**

B.R. Chemicals Co., Ltd.: A 100% subsidiary in Japan engaged in local distribution and export of chemicals


Q3 FY2021-22 EARNINGS WEBINAR

Financials – Profit & Loss (Standalone)*


INR. in millions

Particulars	Q3 FY22	Q2 FY22	Change %	Q3 FY21	Change %
Revenue from operations	924.11	1,020.02	-9%	744.17	+24%
EBITDA	133.82	129.17	+4%	139.42	-4%
Depreciation	6.65	6.51	+2%	7.00	-5%
PBIT	127.17	122.66	+4%	132.42	-4%
Interest	1.95	2.70	-28%	2.11	-8%
PBT	125.22	119.96	+4%	130.31	-4%
Taxation	32.85	29.71	+11%	33.33	-1%
PAT	92.37	90.25	+2%	96.98	-5%
* Not including 100% subsidiary B.R. Chemicals Co., Ltd., Japan		Change % from Q.	2 FY22 to Q3 FY22	Change % from Q3	3 FY21 to Q3 FY22


EBITDA Margins (%)



PAT Margins (%)



EPS (Rs.)



Q3 FY2021-22 EARNINGS WEBINAR


* Not including 100% subsidiary B.R. Chemicals Co., Ltd., Japan

Financials – Balance Sheet (Standalone)*


HVI	1111	lions

Particulars	Q3 FY22	Q2 FY22	Q3 FY21	
Sources of Funds				
Equity Share Capital	51.0	51.0	51.0	
Reserves & Surplus	1081.5	1014.0	757.8	
Net Worth	1132.5	1065.0	808.8	
Deferred Tax	36.0	35.6	35.7	
Loans	-11.1	154.0	217.8	
Total Sources	1157.4	1254.6	1062.3	
Application of Funds				
Gross Block	587.3	575.0	553.4	
Less: Depreciation	256.4	252.1	238.0	
Net Block	330.9	322.9	315.4	
Capital WIP and Right of Lease (net)	114.5	109.8	100.3	
Investments	1.6	1.6	1.6	
Other Non Current Assets	6.0	5.9	5.1	
Current Assets, Loans and Advances				
Inventories	328.7	226.7	254.6	
S. Debtors	563.4	711.5	480.2	
Cash & Bank Balances	54.1	51.0	84.4	
Loans & Advances	1.3	1.3	0.5	
Other Current assets	30.4	33.0	30.0	
Total Current Assets	977.9	1023.5	849.7	
Current Liabilities and Provisions				
S. Creditors	202.7	164.8	147.0	
Other Current Liabilities	54.2	30.6	50.7	
Provisions	16.6	13.8	12.1	
Total Current Liabilities and Provisions	273.5	209.2	209.8	
Total Applications	1157.4	1254.6	1062.3	


Return on Equity (%)



Return on Capital Employed (%)



Total Debt/Equity (X)






Financials – (Standalone)*








Highlights

- Overall product realization per unit increased in both manufacturing and distribution business
- Exports were hampered by high freight costs and reduced overseas demand
- Despite increase in sales of manufactured products, overall revenue was down due to lower sales of meta cresol and isophthalic acid




Financials – Revenue and geographic mix





Financials - Distribution

Total distribution revenue and EBITDA index




Highlights

- Overall increased margin in distribution business due to change in product mix
- Pandemic third wave led to slowdown towards the end of the quarter
- Demand for and price of resorcinol continues to be under pressure due to oversupply in China
- New product addition such as hexamine and neo pentyl glycol expected to augment growth going forward



Financials - Manufacturing

Total manufacturing revenue and EBITDA index




Highlights

- Acrylamide liquid demand was robust in domestic market
- Price of AAM-L increased by more than 15% and that of PAM-L by more than 10%
- Surge in sales of polyacrylamide liquid as new customers added
- Margin in PAM-L reduced due to increase in acrylic acid and caustic prices
- Capacity utilization of 60% in AAM-L and 33% in PAM-L
- AAM-Solids and NMA to add to revenue in Q4 subject to approvals



Acrylonitrile – Acrylamide Price Trend



Q3 FY2021-22 EARNINGS WEBINAR

Outlook for the current quarter: Chemical distribution, and manufacturing

Chemical distribution

- Overall demand which was sluggish at the beginning of the quarter is now picking up subsequent to easing of the pandemic
- Better price realization expected owing to supply disruptions from China resulting in reduced
 product availability

Acrylamide liquid

- Domestic demand remains stable
- Market share expected to increase further
- Falling raw material price expected to boost margins
- Exports expected to pick up towards the end of the quarter

Polyacrylamide liquid

- Market share improving and expecting 50% growth this quarter
- Further improvement to product performance to boost market penetration
- Falling raw material price expected to increase margins



Q3 FY2021-22 EARNINGS WEBINAR

Contact

Mrs. Harshita Shetty

Compliance Officer

Head office

145/A, Mittal Towers Nariman Point, Mumbai 400 021, India

Call / Fax

+91-22-4333-7200

+91-22-2287-3022 (Fax)

Mail to

investor@blackrosechemicals.com